Inhibitors of farnesyl protein transferase
US6602883B1 · kind B1 · utility
11Cited by
18References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 5, 2000 |
| Grant date | Aug 5, 2003 |
| Priority date | — |
| Expiry date | May 5, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D409/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are quinoline and benzazepine derivatives that inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogenic protein Ras. Thus, the compounds are useful as anti-cancer agents. The compounds are also useful in the treatment of diseases other than cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.